ScreenerHero

IOVA Iovance Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · iovance.com
12.91USD-0.35%Mkt Cap: 5.85B $P/E: —

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other so…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.85B USD
Enterprise Value5.62B USD
Revenue (TTM)324.97M USD
Gross Profit90.32M USD
Net Income (TTM)-390.98M USD
Revenue/Share0.79 USD
Last Price12.91 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees975
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-54.68
PEG—
EV/EBITDA-21.64
EV/Revenue17.29
P/S18.06
P/B7.98
EPS (TTM)-0.63
EPS (Forward)-0.24
52W Range
1.76082% of range15.30
52W High15.30 USD
52W Low1.760 USD
Profitability
Gross Margin34.28%
Oper. Margin-52.26%
EBITDA Margin-79.88%
Profit Margin-148.38%
ROE-55.97%
ROA-42.82%
Growth
Revenue Growth65.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-302.41M USD
CapEx (TTM)33.84M USD
FCF Margin-57.79%
FCF Yield-3.21%
Net Debt-251.67M USD
Net Debt/EBITDA0.97
Balance Sheet
Debt/Equity0.07
Current Ratio4.34
Quick Ratio3.74
Book Value/Sh1.63 USD
Cash/Share0.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateSep 26, 2013
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.80 USD
Upside (mean)-0.9%
Target Range6.000 USD – 20.00 USD
6.000-0.9% to mean20.00
# Analysts10
Ownership
Shares Out.452.97M
Float394.31M
Insiders0.35%
Institutions70.70%
Short Interest
Short Ratio6.0d
Short % Float20.57%
Short % Out.19.23%
Shares Short87.13M
Short (prev mo.)102.94M
Technical
SMA 508.616 (+49.9%)
SMA 2004.844 (+166.6%)
Beta0.76
S&P 52W Chg16.45%
Avg Vol (30d)16.99M
Avg Vol (10d)21.87M
Technical Indicators
RSI (14)66.5
MACD1.6342
MACD Signal1.5662
MACD Hist.+0.0680
BB Upper15.73 USD
BB Middle11.24 USD
BB Lower6.751 USD
BB Width79.88%
ATR (14)0.8552 USD
Vol Ratio (20d)0.80x